The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.
DIO-901 is expected to begin Phase II clinical testing later in 2008 and has received fast track status from the FDA, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.
David Cory, CEO of DiObex, said: “DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal.”